Flupentixol decanoate
Brand names: Depixol, Modecate
Flupentixol decanoate is a long-acting depot formulation of the thioxanthene antipsychotic flupentixol, given by deep intramuscular injection for maintenance treatment of schizophrenia and related psychoses.
ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.
Clinical monograph
How it works
After injection the decanoate ester is slowly hydrolysed to release flupentixol, which antagonises dopamine D2 receptors to provide sustained antipsychotic effect.
Prescribing in practice
- A test dose is required before establishing maintenance therapy because the long action means adverse effects, including extrapyramidal reactions, are not readily reversible.
- As with oral flupentixol, avoid in overactive or excited patients owing to a potential alerting effect.
- Antipsychotics carry risks of QT prolongation and increased stroke and mortality in elderly patients with dementia.
Monitoring
Monitor for extrapyramidal symptoms, injection-site reactions and metabolic and cardiac effects throughout depot treatment.
Counselling the patient
- This is a long-acting injection given at regular intervals by a health professional.
- Report muscle stiffness, restlessness, tremor or high fever.
- Keep follow-up appointments so treatment can be monitored and adjusted.
Evidence & guidelines
Long-acting antipsychotic injections are an established maintenance strategy for improving adherence in schizophrenia.
Reference: Maudsley Prescribing Guidelines; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).
Related
Curated clinical cross-links plus same-class fallbacks.
- Acute Behavioural Disturbance / Rapid Tranquillisation · RCEM 2022; RCPsych 2022; NICE NG10
- Self-Harm Presentation · NICE NG225 (2022)
- Capacity Assessment (Mental Capacity Act) · MCA 2005; Code of Practice
- Acute Psychosis Management · NICE CG178 2014
- Depression Management · NICE CG90 2022
- Lithium Therapy Monitoring · NICE CG185